Caie Peter D, Zhou Ying, Turnbull Arran K, Oniscu Anca, Harrison David J
Quantitative and Digital Pathology, School of Medicine, University of St Andrews, St Andrews, KY16 9TF, UK.
Digital Pathology Unit, Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, UK.
Oncotarget. 2016 Jul 12;7(28):44381-44394. doi: 10.18632/oncotarget.10053.
A number of candidate histopathologic factors show promise in identifying stage II colorectal cancer (CRC) patients at a high risk of disease-specific death, however they can suffer from low reproducibility and none have replaced classical pathologic staging. We developed an image analysis algorithm which standardized the quantification of specific histopathologic features and exported a multi-parametric feature-set captured without bias. The image analysis algorithm was executed across a training set (n = 50) and the resultant big data was distilled through decision tree modelling to identify the most informative parameters to sub-categorize stage II CRC patients. The most significant, and novel, parameter identified was the 'sum area of poorly differentiated clusters' (AreaPDC). This feature was validated across a second cohort of stage II CRC patients (n = 134) (HR = 4; 95% CI, 1.5- 11). Finally, the AreaPDC was integrated with the significant features within the clinical pathology report, pT stage and differentiation, into a novel prognostic index (HR = 7.5; 95% CI, 3-18.5) which improved upon current clinical staging (HR = 4.26; 95% CI, 1.7- 10.3). The identification of poorly differentiated clusters as being highly significant in disease progression presents evidence to suggest that these features could be the source of novel targets to decrease the risk of disease specific death.
一些候选组织病理学因素在识别具有疾病特异性死亡高风险的II期结直肠癌(CRC)患者方面显示出前景,然而它们可能存在再现性低的问题,且没有一个因素能取代经典的病理分期。我们开发了一种图像分析算法,该算法对特定组织病理学特征的量化进行了标准化,并输出了无偏差捕获的多参数特征集。在一个训练集(n = 50)中执行该图像分析算法,并通过决策树建模对所得的大数据进行提炼,以识别对II期CRC患者进行亚分类最具信息量的参数。识别出的最显著且新颖的参数是“低分化簇的总面积”(AreaPDC)。在另一组II期CRC患者(n = 134)中对该特征进行了验证(HR = 4;95% CI,1.5 - 11)。最后,将AreaPDC与临床病理报告中的显著特征、pT分期和分化情况整合为一个新的预后指数(HR = 7.5;95% CI,3 - 18.5),该指数优于当前的临床分期(HR = 4.26;95% CI,1.7 - 10.3)。低分化簇在疾病进展中具有高度显著性这一发现表明,这些特征可能是降低疾病特异性死亡风险的新靶点来源。